GIG HARBOR, Wash., Dec. 04, 2025 (GLOBE NEWSWIRE) -- IP Strategy (Nasdaq: IPST) (the “Company”), the first Nasdaq-listed digital asset treasury (DAT) centered on the $IP token, today announced a major advancement in its validator operations to significantly expand is on-chain revenue engine: the initiation of long-term self-staking under custodial accounts at Crypto.com. The transition to long-term staking on the Company’s validator is expected to increase overall yields to approximately 11.72%, more than d ...

Core Insights - Akari Therapeutics is advancing a new class of immuno-oncology antibody drug conjugates (ADCs) utilizing a novel PH1 payload designed to target and disrupt the spliceosome, showing promising preclinical efficacy and safety profiles [3][4] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and is set to enter IND-enabling studies with plans for clinical trials in Q4 2026 [3][4] Company Overview - Akari Therapeutics specializes in developing next-generation spliceosome payload ADCs, differentiating itself from traditional ADCs that use tubulin inhibitors and DNA damaging agents [4] - The PH1 payload is a spliceosome modulator that disrupts RNA splicing in cancer cells, leading to cancer cell death and activation of immune responses [4] Product Development - AKTX-101 has demonstrated significant activity and prolonged survival in preclinical studies compared to traditional ADCs, with potential for synergy with checkpoint inhibitors [4] - The company is generating validating data on the PH1 payload to advance AKTX-101 and explore other undisclosed targets [4]

OMER, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leader in AI-powered visual sensing and Predictive Maintenance (PdM) solutions, announces the successful completion of a Proof of Concept (POC) project in the global mine truck segment conducted with a major international automotive OEM. As part of the evaluation, Odysight.ai’s solution was installed on an 8x4 heavy-duty mine truck chassis. The system was fully integrated into the vehicle’s structural framework to enable cont ...

Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission for FDA approval for the use of Ameluz® on all non-face and scalp areas WOBURN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of p ...

In a newly released interview, CEO Matt Edelman outlines Super League’s growth strategy, revenue opportunities, and vision for scaling shareholder value. SANTA MONICA, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Super League (Nasdaq: SLE) (the “Company”), a leader in playable media trusted by global brands to reach and activate gaming audiences through playable ads and gamified content, today announced the release of a new interview featuring Chief Executive Officer Matt Edelman. In the discussion, Edelman pr ...

Companies turn to independent professionals to power digital operations with human touch, but skill gaps loom as a top challenge for 39% of businesses heading into 20261 PALO ALTO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Upwork Inc. (Nasdaq: UPWK), the world’s human and AI-powered work marketplace, today released its Monthly Hiring Report for November, finding that amid the race to scale AI systems, demand is rising for human-centered skills to reinforce work quality, uplevel communication and creativity, ...

Core Insights - Alpha Tau Medical Ltd. is advancing its innovative alpha-radiation cancer therapy, Alpha DaRT, with a multi-center clinical trial for pancreatic cancer in the U.S. expected to complete patient recruitment by the end of Q1 2026 [1][2] - The company will present two abstracts at the 2026 ASCO Gastrointestinal Cancers Symposium, showcasing data from its recently completed pilot trial in Montreal [1][2] Company Overview - Alpha Tau Medical Ltd. was founded in 2016 and focuses on the research, development, and potential commercialization of Alpha DaRT for treating solid tumors [4] - The technology was developed by professors from Tel Aviv University, emphasizing its academic foundation [4] Clinical Trial Details - The U.S. multi-center pancreatic cancer clinical trial began patient treatment in September 2025 and aims to enroll up to 30 patients with newly diagnosed pancreatic cancer [2] - Approximately 87% of newly diagnosed pancreatic cancer patients are deemed inoperable, highlighting the significant unmet medical need [2] Technology Description - Alpha DaRT utilizes radium-224 for intratumoral delivery, allowing for targeted alpha-irradiation of solid tumors while minimizing damage to surrounding healthy tissue [3]

SANTA MONICA, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- JAKKS Pacific, Inc. (NASDAQ: JAKK), a leading designer and marketer of toys, and The Hershey Company, one of the world’s largest confectionery brands, announced today a new partnership that will bring the beloved Hershey branding to JAKKS Pacific’s popular Charming line of small dolls and collectibles, marking the first-ever confection-themed expansion of the fashionable mini-doll brand. The collection will consist of eight SKUs featuring dolls inspir ...

Core Viewpoint - Astec Industries, Inc. has signed a definitive agreement to acquire CWMF Corporation, a manufacturer of asphalt plant equipment with annual revenues of approximately $50 million, primarily serving the Midwest, South-Central, and Great Lakes regions of the United States [1][2]. Group 1: Acquisition Details - The acquisition of CWMF is aligned with Astec's disciplined growth strategy and is expected to be efficiently integrated due to the strong cultural fit between the two organizations [2]. - The transaction is anticipated to close in the first quarter of 2026 and is projected to be accretive from day one, with the consolidated net leverage ratio expected to remain within the previously disclosed range of 1.5 to 2.5 times net debt to adjusted EBITDA [2]. Group 2: Company Overview - Astec is a manufacturer specializing in equipment for asphalt road building, aggregate processing, and concrete production, with operations divided into two primary segments: Infrastructure Solutions and Materials Solutions [3]. - Infrastructure Solutions includes the design, engineering, manufacturing, and marketing of asphalt and concrete plants, along with related components and heavy equipment [3]. - Materials Solutions focuses on heavy and soft rock processing equipment, servicing, and supplying parts for various markets including aggregate, civil construction, energy, mining, and recycling [3].

Core Points - Synchronoss Technologies, Inc. is set to be acquired by Lumine Group Inc. in an all-cash transaction valued at approximately $116.4 million in equity and $258.4 million in enterprise value, transitioning the company to a privately held entity [1][4] - Shareholders of Synchronoss will receive $9.00 per share, representing a 70% premium over the closing price prior to the announcement [2][4] - The acquisition aims to enhance growth and innovation opportunities for Synchronoss, allowing it to leverage Lumine Group's diversified portfolio [3][4] Company Overview - Synchronoss is a global leader in personal cloud platforms, providing secure connections for service providers and millions of subscribers [7][8] - The company has over 200 petabytes of data stored and a significant global subscriber base [3] Acquisition Details - The transaction has been unanimously approved by Synchronoss's Board of Directors and is expected to close in the first half of 2026, pending shareholder and regulatory approvals [4][5] - Approximately 21% of Synchronoss's outstanding shares have been committed to vote in favor of the transaction [5] Strategic Implications - The acquisition is expected to provide immediate value to shareholders and position Synchronoss for long-term growth, enhancing its capabilities in mobile cloud storage solutions [3][4] - Lumine Group's first acquisition of a public company reinforces its mission to support customers' brands and solutions through perpetual ownership [4]